Study on Osteoarthritis at Tertiary Care Centre and How to Diagnose
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Summary Analgesics Dec2019
Status as of December 31, 2019 UPDATE STATUS: N = New, A = Advanced, C = Changed, S = Same (No Change), D = Discontinued Update Emerging treatments for acute and chronic pain Development Status, Route, Contact information Status Agent Description / Mechanism of Opioid Function / Target Indication / Other Comments Sponsor / Originator Status Route URL Action (Y/No) 2019 UPDATES / CONTINUING PRODUCTS FROM 2018 Small molecule, inhibition of 1% diacerein TWi Biotechnology / caspase-1, block activation of 1 (AC-203 / caspase-1 inhibitor Inherited Epidermolysis Bullosa Castle Creek Phase 2 No Topical www.twibiotech.com NLRP3 inflamasomes; reduced CCP-020) Pharmaceuticals IL-1beta and IL-18 Small molecule; topical NSAID Frontier 2 AB001 NSAID formulation (nondisclosed active Chronic low back pain Phase 2 No Topical www.frontierbiotech.com/en/products/1.html Biotechnologies ingredient) Small molecule; oral uricosuric / anti-inflammatory agent + febuxostat (xanthine oxidase Gout in patients taking urate- Uricosuric + 3 AC-201 CR inhibitor); inhibition of NLRP3 lowering therapy; Gout; TWi Biotechnology Phase 2 No Oral www.twibiotech.com/rAndD_11 xanthine oxidase inflammasome assembly, reduced Epidermolysis Bullosa Simplex (EBS) production of caspase-1 and cytokine IL-1Beta www.arraybiopharma.com/our-science/our-pipeline AK-1830 Small molecule; tropomyosin Array BioPharma / 4 TrkA Pain, inflammation Phase 1 No Oral www.asahi- A (ARRY-954) receptor kinase A (TrkA) inhibitor Asahi Kasei Pharma kasei.co.jp/asahi/en/news/2016/e160401_2.html www.neurosmedical.com/clinical-research; -
List of Union Reference Dates A
Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov. -
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products. -
(12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen Et Al
USOO9005660B2 (12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen et al. (45) Date of Patent: Apr. 14, 2015 (54) IMMEDIATE RELEASE COMPOSITION 4,873,080 A 10, 1989 Bricklet al. RESISTANT TO ABUSEBY INTAKE OF 4,892,742 A 1, 1990 Shah 4,898,733. A 2f1990 DePrince et al. ALCOHOL 5,019,396 A 5/1991 Ayer et al. 5,068,112 A 11/1991 Samejima et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 5,082,655 A 1/1992 Snipes et al. Jan Martin Oevergaard, Frederikssund 5,102,668 A 4, 1992 Eichel et al. 5,213,808 A 5/1993 Bar Shalom et al. (DK); Joakim Oestman, Lomma (SE) 5,266,331 A 11/1993 Oshlack et al. 5,281,420 A 1/1994 Kelmet al. (73) Assignee: Egalet Ltd., London (GB) 5,352.455 A 10, 1994 Robertson 5,411,745 A 5/1995 Oshlack et al. (*) Notice: Subject to any disclaimer, the term of this 5,419,917 A 5/1995 Chen et al. patent is extended or adjusted under 35 5,422,123 A 6/1995 Conte et al. U.S.C. 154(b) by 473 days. 5,460,826 A 10, 1995 Merrill et al. 5,478,577 A 12/1995 Sackler et al. 5,508,042 A 4/1996 OShlack et al. (21) Appl. No.: 12/701.248 5,520,931 A 5/1996 Persson et al. 5,529,787 A 6/1996 Merrill et al. (22) Filed: Feb. 5, 2010 5,549,912 A 8, 1996 OShlack et al. -
Oxaceprol Monotherapy Versus Oxaceprol and Glucosamine Combination Therapy for Knee Osteoarthritis
Original Article ISSN (Print) : 2454-8952 International Journal of Medical and Dental Sciences, Vol 9(2), DOI: 10.18311/ijmds/2020/24871, July 2020 ISSN (Online) : 2320-1118 Oxaceprol Monotherapy versus Oxaceprol and Glucosamine Combination Therapy for Knee Osteoarthritis Vijay Kumar1, Sanjeev Sareen2, Shrey Bhatia3* 1Professor and Head, Department of Pharmacology, Government Medical College, Patiala – 147001, Punjab, India 2Associate Professor, Department of Orthopaedics, Government Medical College, Patiala – 147001, Punjab, India 3Junior Resident, Department of Pharmacology, Government Medical College, Patiala – 147001, Punjab, India; [email protected] Abstract Introduction: Osteoarthritis (OA) is the commonest form of arthritis which presents with joint pain and functional limitations. Oxaceprol, a derivative of hydroxyproline, inhibits leukocyte migration into the joints thus inhibiting Proline in chondrocytes. Aims and Objective: Glucosamineinflammatory combination process. Oxaceprol therapy also in patients increases diagnosed availability with of Knee Glucosamine Osteoarthritis and improving (KOA). Materials uptake ofand Glucosamine Methods: Thisand To demonstrate efficacy of Oxaceprol Monotherapy versus Oxaceprol and randomly received either Oxaceprol 600mg OD for 4 weeks, or combination of Oxaceprol 600mg OD and Glucosamine was an open labelled, parallel group, Randomized Controlled Trial where 40 adults age ≥50 years diagnosed with KOA visual analogue scale (VAS) recording from baseline to 4 weeks of treatment. Results: Our study showed that both Oxaceprol monotherapySulphate 1500mg (group OD A, for n=20), 4 weeks. and GlucosamineThe patients pluswere Oxaceprol analysed ascombination per the differences therapy (group between B, n=20) WOMAC improved scale scores, joint pain, and stiffness, and functionality as shown by analysing WOMAC scores before, and after 4 weeks of treatment. -
La. ADMINISTRATION of DAMAN & DIU OFFICE of the HEAD of OFFICE/HEALTH OFFICER GOVERNMENT HOSPITAL, DIU (362 520)
iiv utsr T;3Tvr V ifta UTrTT Farf% T 3r d (Z9't 3r-4c Tom) WT 4114C414, i TWt 3TF9c1I i, i la-362520. ir. ii3r41/ii T/1(2)/1 -20/2016-2017/301. fka* :- 02/08/2016. *-fr Wr3W) SMi T i ' i 'i11 * AT * ialft r Citct']^1 q T-^r&T (iriq+rf1 379ciis), ,1"d q, F71Ftq * , , U)' UM 79 M-401 3rt9'Trci, t a 4 111AIREF, Tc 'lr1 Lrd *U u hC iit rl *t 3TiV i f^lv ft &M WiiW W04cii3T1icn1b cr $1cci1/3rrqpV^ft34 i1 http_//daman.nprocure.com qi 3i- T fWf T 3Trr 9 I f1T 7W www. daman.nic.in qi 3ft < 6 t I WA i41j1f4 #f WT fur 3T ;5r7 T Tft (ftwfg fir N1i Ic i * Tr ) (3i,i1 ) 2. 3. 4. 01. iii T1Zp Fszi Er11 r Lrcr iri^rtl T. 4,50,000/- T. 2,000/- 3rF^-T1 cam, i a ' fv "'A iii V r c iff *+ is1$d 3T1- T T 1 f t ZR 4,A 3i3 c S WE# *t 3rfc r M ft :- 23/08/2016 41 12.00 Wi1 ^W. 3 i r a - l T 3 1 f r i tc I .,i V 9 1 t *r 3i1 err :- 23/08/2016 ;E^t 13.00 a4 -TW. Ar r ft 3ird-c i:T i)W# *t itrr :- 1 mm T3Tr t 23/ 08/2016 ;E^t 16.00 W4. f l ih1 -sir ift cr if s u1Tq 4 www.nprocure.com W{ 3rfc'IJR arilzrr T iRm i vf^ff v i i t m e1Jrr I vi^w ft ftDqpj AiTq i f! S # 1 fPjf^r # Fi Ti Tf f f + Tr i TVIU I f'df i S r &A. -
Perspektive 2023
Perspektive 2023 Neue Medikamente in Entwicklung Inhalt 2 Neue Medikamente in Sicht 6 Neue Wege 8 Neue Chancen für Krebspatienten 10 Entzündungen zum Erliegen bringen 13 Infektionen bekämpfen 14 Gegen Krankheiten unterschiedlichster Art 16 Kindermedikamente und Orphan Drugs 19 Medikamente für Männer und Frauen 20 Die neuen Wirkstoffe 23 Der Beitrag Deutschlands 26 Projekte, die bis 2023 zu einer Zulassung führen können 44 Schwerpunkte der vfa-Mitglieder 46 Kontakt Blick voraus Mehr als zehn Jahre dauert es von der Idee bis zur Zulassung, manch- mal mehr als zwanzig. Erfolge mit neuen Medikamenten kann also nur ernten, wer lange vorher gesät hat. Das haben die forschenden Pharma-Unternehmen des vfa in den späten 2000er- und frühen 2010er-Jahren reichlich getan, so dass nun besonders viele Medika- mente in ihrer Erprobung weit fort geschritten sind. Welche es noch vor Ende 2023 bis zu einer Zulassung oder Zulassungserweiterung schaffen könnten, zeigt diese Veröffentlichung. Sie macht deutlich, dass zahlreiche Patientinnen und Patienten gute Aussichten auf bessere Behandlungsmöglich keiten für ihre Leiden haben. vfa – die forschenden Pharma-Unternehmen Perspektive 2023 Neue Medikamente in Sicht Viele Krankheiten sind in den letzten Jahren besser behandelbar geworden, und Patienten und Ärzte hoffen, dass dieser Strom des Fortschritts nicht abreißt. Die Chancen dafür stehen gut. Denn forschende Pharma-Unternehmen entwickeln derzeit gegen mehr als 145 Krankheiten Medikamente, die bis spätestens Ende 2023 die Zulassung erhalten könnten. Das zeigt eine Erhebung des vfa bei seinen Mitgliedsunter nehmen vom Oktober 2019. Demnach könnten bis Ende 2023 insgesamt 434 Sämtliche Projekte, die in der Erhebung erfasst ihrer Projekte zu einer Zulassung oder Zulassungs- wurden, sind ab S. -
Diclofenac in the Treatment of Pain in Patients with Rheumatic Diseases
Review paper Reumatologia 2018; 56, 3: 174–183 DOI: https://doi.org/10.5114/reum.2018.76816 Diclofenac in the treatment of pain in patients with rheumatic diseases Justyna Kołodziejska, Michał Kołodziejczyk Department of Pharmaceutical Technology, Chair of Applied Pharmacy, Medical University of Lodz, Poland Abstract Diclofenac, a phenylacetic acid derivative, is a drug demonstrating high efficacy after oral adminis- tration in the treatment of pain and physical disability in rheumatic diseases. In view of the adverse effects associated with using diclofenac, it is necessary to consider all known drug safety informa- tion before the drug is selected for therapy and the dosage regimen is set for individual patients. Selecting an oral dosage form with specific properties determined by excipients is a method to im- prove the availability of the drug substance and, at the same time, minimize adverse drug reactions. An alternative to tablet or capsule dosage forms is diclofenac application to the skin. The proven efficacy of this method is further improved through the use of transdermal penetration enhancers and vehicle ingredients which provide dosage forms with specific physical properties. Key words: diclofenac, efficacy, adverse effects, dosage form technology. Introduction on the market also exhibit technological differences (dosage form modifications). Intense pharmacological Diseases of the musculo-skeletal system affect 70% and formulation research is currently being conducted of the population over the age of 50 years. Pain caused to obtain more effective and safer products [2]. by rheumatic diseases decreases or resolves during re- NSAIDs are effective in multiple indications. In rheu- mission-inducing treatment. Drugs used in the therapy matology, they are used in the treatment of a range of of rheumatic diseases usually have a late onset of ac- diseases including rheumatoid arthritis, lupus erythe- tion. -
DMM Model of Osteoarthritis
WHY DOES MY JOINT HURT: UNDERSTANDING DISEASE PHENOTYPE AND PAIN RELATIONSHIPS USING MOUSE MODELS OF ARTHRITIS Sanaa Zaki A thesis submitted in fulfilment of requirements for the degree of Doctor of Philosophy Faculty of Medicine (Sydney Medical School) The University of Sydney November 2016 i PREFACE The research embodied in this thesis was conducted at the Raymond Purves Laboratories of Bone and Joint Research, Kolling Institute of Medical Research, University of Sydney at the Royal North Shore Hospital, St Leonards, Australia. Institutional ethics committee approval was sought and obtained prior to the commencement of all animal experiments. The research was partly funded by Arthritis Australia. I certify that the intellectual content of this thesis is the product of my own work, including the design, conduct and analysis of experiments presented in this thesis. Contributions of other researchers and all the assistance received in preparing this thesis and relevant sources have been acknowledged. This thesis has not been submitted for any degree or other purpose. Sanaa Zaki ii ACKNOWLEDGEMENTS My PhD candidature has been a very long journey and I have many colleagues, friends and family that I need to acknowledge for their contribution. Firstly, I am forever indebted to the support and mentorship of my two supervisors, Mark Connor and Chris Little. They graciously bestowed me with the freedom to pave my own path of scientific discovery, while always being there to guide and redirect me when I needed it the most. I am truly indebted to their academic brilliance, scientific rigor and boundless patience. They are truly inspirational researchers that I can only hope to, one day, emulate. -
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department -
Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01 -
This Year 2017 in Aperplexing World
sph this year 2017 in a perplexing world. in aperplexing THOUGHT “ Our core purpose commits us to redouble our eort to ensure that we narrow these divides to produce the science and scholarship that contributes to a better, healthier world for all.” DEAR COLLEAGUES: WELCOME TO SPH THIS YEAR, our School’s us to always ask what the role of public health is in annual report. these changing times. To that end, while in this issue Our School’s core purpose is “Think. Teach. Do. of SPH This Year we feature the work of the School, For the health of all.” This aims to describe and we also feature 23 deans and program directors of animate what we do: we generate ideas through our other schools and programs talking about the role scholarship and research, think; we transmit this of public health in these times—their comments knowledge to the next generation, teach; and we work are captured on pages 46 to 49 of this issue and on to communicate these ideas and be a part of the the web at bu.edu/sph/thisyear17—who create a action that contributes to a healthier world, do. This compelling portrait of the central role that academic issue of SPH This Year focuses on our scholarship at public health stands to play in the years ahead. Thank a time when thought and science have become more you to all of our colleagues who participated in these important than ever. interviews; we learned from all your comments and Over the past year, we have seen the country— are excited to work together in the coming years.